The story has been updated to include comments from a conference call.

NEW YORK (GenomeWeb News) – Agilent Technologies and Swedish private equity firm EQT today announced that Agilent will acquire cancer diagnostics firm Dako from EQT for $2.2 billion.

The deal, the largest in Agilent's history, is expected to close within the next 60 days and moves Agilent deeper into the diagnostics space.

Agilent is funding the deal entirely with its off-shore cash.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.